These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 19443382)
1. CYP17 gene polymorphism and its association in north Indian prostate cancer patients. Sobti RC; Gupta L; Thakur H; Seth A; Singh SK; Kaur P Anticancer Res; 2009 May; 29(5):1659-63. PubMed ID: 19443382 [TBL] [Abstract][Full Text] [Related]
2. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764 [TBL] [Abstract][Full Text] [Related]
3. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806 [TBL] [Abstract][Full Text] [Related]
4. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959 [TBL] [Abstract][Full Text] [Related]
5. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Gsur A; Bernhofer G; Hinteregger S; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M Int J Cancer; 2000 Aug; 87(3):434-7. PubMed ID: 10897051 [TBL] [Abstract][Full Text] [Related]
6. Lack of association between CYP17 Mspa1 polymorphism and prostate cancer risk: a meta-analysis of 14494 cases and 15971 controls. Song G; Gu L; Tian F; Bao Q; Tang Z; Wang S Medicina (Kaunas); 2013; 49(2):51-5. PubMed ID: 23888338 [TBL] [Abstract][Full Text] [Related]
7. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Verla-Tebit E; Wang-Gohrke S; Chang-Claude J Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450 [TBL] [Abstract][Full Text] [Related]
8. [Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men]. Guli MR; Wang JQ; Zhang JX; Deng G Zhonghua Nan Ke Xue; 2006 Feb; 12(2):120-2. PubMed ID: 16519145 [TBL] [Abstract][Full Text] [Related]
9. No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk. dos Santos A; Ribeiro ML; Mesquita JC; Carvalho-Salles AB; Hackel C Prostate Cancer Prostatic Dis; 2002; 5(1):28-31. PubMed ID: 15195127 [TBL] [Abstract][Full Text] [Related]
10. CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population. Souiden Y; Mahdouani M; Chaieb K; Elkamel R; Mahdouani K Cancer Epidemiol; 2011 Oct; 35(5):480-4. PubMed ID: 21193363 [TBL] [Abstract][Full Text] [Related]
11. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia. Tigli H; Yazici H; Dalay N Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129 [TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073 [TBL] [Abstract][Full Text] [Related]
13. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. Sobti RC; Onsory K; Al-Badran AI; Kaur P; Watanabe M; Krishan A; Mohan H DNA Cell Biol; 2006 May; 25(5):287-94. PubMed ID: 16716118 [TBL] [Abstract][Full Text] [Related]
14. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Sobti RC; Gupta L; Singh SK; Seth A; Kaur P; Thakur H Cancer Genet Cytogenet; 2008 Sep; 185(2):78-85. PubMed ID: 18722876 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer associated with CYP17 genotype. Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544 [TBL] [Abstract][Full Text] [Related]
16. Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. Vesovic Z; Herkommer K; Vogel W; Paiss T; Maier C Anticancer Res; 2005; 25(2B):1303-7. PubMed ID: 15865082 [TBL] [Abstract][Full Text] [Related]
17. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China. Hou L; Xu J; Gao YT; Rashid A; Zheng SL; Sakoda LC; Shen MC; Wang BS; Deng J; Han TQ; Zhang BH; Meyers DA; Fraumeni JF; Hsing AW Int J Cancer; 2006 Jun; 118(11):2847-53. PubMed ID: 16381022 [TBL] [Abstract][Full Text] [Related]
18. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Allen NE; Forrest MS; Key TJ Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586 [TBL] [Abstract][Full Text] [Related]
19. A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss. Sata F; Yamada H; Yamada A; Kato EH; Kataoka S; Saijo Y; Kondo T; Tamaki J; Minakami H; Kishi R Mol Hum Reprod; 2003 Nov; 9(11):725-8. PubMed ID: 14561815 [TBL] [Abstract][Full Text] [Related]
20. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Ntais C; Polycarpou A; Ioannidis JP Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):120-6. PubMed ID: 12582021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]